Sky Bio Limited provides prospective clients with a Management, Marketing and Investment Consultancy service for UK and international clients who are predominantly in the healthcare and healthcare equipment market.
We gather and present information on the very latest healthcare equipment, machines and drugs which will include sourcing, cost analysis and best use so that they can make the correct choices and purchase for the most competitive prices using our excellent business relationships with a number of leading international manufactures, suppliers and retailers.
We also offer in-depth advice and mediate health investments in the healthcare sectors, including cross country investments such as UK to Turkey.
Somaserve is a UCL spin out, a uniquely positioned specialist reagent and pharma service business which exploits the proprietary polyNaut™ technology (a ‘bionic’ nanoparticle vesicle). The reagent products are highly differentiated and address an unfulfilled area in the live cell imaging market. The ‘fee for service’ offering solves molecule viability problems for clients presenting a new approach to drug discovery.
Watch our Member Showcase Video https://bit.ly/3IheAwt
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
Sphere Fluidics Limited has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours
SRG is an award-winning market leader, delivering innovative and bespoke resourcing solutions to the broad-based scientific industries. Our expertise spans all scientific-based industries, from forensic, pharmaceutical, medical devices, biotechnology and chemical, through to renewable energy and nanotechnology. Each day we help scientists who are passionate about the future to develop their careers in a world that is ever-changing. We have been successfully serving the scientific sector since 1990. The vast majority of our consultants and managers are qualified scientists, so they talk your language, understand your challenges and can interpret and meet your needs.
St John's Innovation Centre was established by St John's College, part of the University of Cambridge, in 1987 to provide early-stage, knowledge-based companies with business advice, strategic consultancy, introductions and flexible accommodation. It was the first innovation centre of its kind in Europe and has become world renowned for its success as a business incubator. St John's Innovation Centre exists to provide a dynamic and supportive incubation environment to accelerate the growth of ambitious innovative firms in the Cambridge region. It is privately owned and commercially managed.
Standigm UK is a UK subsidiary of Standigm Inc.; an AI drug discovery company headquartered in Seoul, South Korea. Pursuing full-stack, AI-driven industrialisation of drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target identification, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. Standigm has raised $71.2M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world. Standigm UK was incorporated in September 2021 and started to expand its movement in the European area by making new collaborations and expanding its R&D scope.